News Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Real-time Estimate Cboe BZX Other stock markets 10:12:11 06/05/2024 pm IST			5-day change	1st Jan Change
0.741 ^USD	-0.46%		+2.85%	-75.08%

15/03	North American Morning Briefing : Inflation -2-	DJ
14/03	Top Midday Decliners	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spruce Biosciences : Pediatric Endocrine Society 2024 Annual Meeting	03/05	PU
Spruce Biosciences : Failure to Satisfy Listing Rule - Form 8-K	02/05	PU
Spruce Biosciences to Participate in May Investor Conferences	02/05	BU
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	01/05	BU
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	23/04	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	05/04	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	28/03	PR
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21/03	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	20/03	PR
North American Morning Briefing : Inflation -2-	15/03	DJ
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	15/03	BU
Top Midday Decliners	15/03	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	14/03	MT
HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy	14/03	MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating	14/03	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	14/03	MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9	14/03	MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy	14/03	MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy	14/03	MT
Spruce Biosciences Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $2 From $9, Shares Plunge Pre-Bell; Speculative Risk Kept	14/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Summary

Filters